Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rybak

Showing results (111-120 of 531) with videos related to

Pageof 54
Sort By:
Antimicrobial Agents and Chemotherapy|April 24, 2003
Daptomycin dose-effect relationship against resistant gram-positive organismsRaymond Cha, Richard G Grucz, Michael J Rybak
Antimicrobial Agents and Chemotherapy|April 24, 2003
Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a releaseElizabeth A Coyle, Raymond Cha, Michael J Rybak
The Journal of Antimicrobial Chemotherapy|July 4, 2002
Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faeciumRenee-Claude Mercier, Carmine Stumpo, Michael J Rybak
The Mount Sinai Journal of Medicine, New York|February 1, 1986
Concurrent and noncontiguous squamous and transitional cell carcinomas of a bladderS S Tabibzadeh, B J Rybak, R Falcone
Antimicrobial Agents and Chemotherapy|May 6, 2009
Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetationsSteven N Leonard, Céline Vidaillac, Michael J Rybak
Antimicrobial Agents and Chemotherapy|July 18, 2002
In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic modelGeorge P Allen, Raymond Cha, Michael J Rybak
Pharmacotherapy|December 26, 2003
Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic modelRaymond Cha, Ronda L Akins, Michael J Rybak
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|April 11, 2012
Macrolides and staphylococcal biofilmsJorge Parra-Ruiz, Céline Vidaillac, Michael J Rybak
DICP : the Annals of Pharmacotherapy|May 1, 1990
CefiximeN J Leggett, C Caravaggio, M J Rybak
The Journal of Infectious Diseases|April 28, 2009
Accessory gene regulator dysfunction: an advantage for Staphylococcus aureus in health-care settings?George Sakoulas, Pamela A Moise, Michael J Rybak
Pageof 54

Showing results (111-120 of 531) with videos related to

Sort By:
Pageof 54
Antimicrobial Agents and Chemotherapy|April 24, 2003
Daptomycin dose-effect relationship against resistant gram-positive organismsRaymond Cha, Richard G Grucz, Michael J Rybak
Antimicrobial Agents and Chemotherapy|April 24, 2003
Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a releaseElizabeth A Coyle, Raymond Cha, Michael J Rybak
The Journal of Antimicrobial Chemotherapy|July 4, 2002
Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faeciumRenee-Claude Mercier, Carmine Stumpo, Michael J Rybak
The Mount Sinai Journal of Medicine, New York|February 1, 1986
Concurrent and noncontiguous squamous and transitional cell carcinomas of a bladderS S Tabibzadeh, B J Rybak, R Falcone
Antimicrobial Agents and Chemotherapy|May 6, 2009
Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetationsSteven N Leonard, Céline Vidaillac, Michael J Rybak
Antimicrobial Agents and Chemotherapy|July 18, 2002
In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic modelGeorge P Allen, Raymond Cha, Michael J Rybak
Pharmacotherapy|December 26, 2003
Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic modelRaymond Cha, Ronda L Akins, Michael J Rybak
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|April 11, 2012
Macrolides and staphylococcal biofilmsJorge Parra-Ruiz, Céline Vidaillac, Michael J Rybak
DICP : the Annals of Pharmacotherapy|May 1, 1990
CefiximeN J Leggett, C Caravaggio, M J Rybak
The Journal of Infectious Diseases|April 28, 2009
Accessory gene regulator dysfunction: an advantage for Staphylococcus aureus in health-care settings?George Sakoulas, Pamela A Moise, Michael J Rybak
Pageof 54